ACCESS Newswire
22 Apr 2019, 18:31 GMT+10
SAN MATEO, CA / ACCESSWIRE / April 22, 2019 / Allysta Pharmaceuticals, Inc. (Allysta) today announced that Kathryn Crawford, Ph.D., the company's Vice President and Head of Non-Clinical Development, will present at the Annual Meeting of ARVO, in Vancouver, British Columbia. Dr. Crawford will present new data on the effects of ALY688, an adiponectin analogue, in a rabbit model of dry eye disease.
In a session covering dry eye disease on Sunday April 28, 8:00 - 9:45 am, Allysta will present the following poster:
305 - B0444 Effects of ALY688 on Atropine-InducedDry Eye in Rabbits. Kathryn S. Crawford, C. Schuh, J. Schuh, H. Hsu
About ARVO
The Association for Research in Vision and Ophthalmology (ARVO) is the largest and most respected eye and vision research organization in the world. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. The Annual Meeting is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries.
About Allysta Pharmaceuticals, Inc.
Allysta is a privately-held biopharmaceutical company developing first-in-class peptide therapeutics with a focus in dry eye and liver diseases. The company's lead compound, ALY688, acts as an agonist of the adiponectin receptor and induces adiponectin-like responses. Since its discovery more than 20 years ago as a major hormone produced by adipocytes and other cell types, many studies have shown that adiponectin has beneficial actions on multiple organs and cell types because of its anti-inflammatory, insulin-sensitizing, anti-atherogenic, anti-steatotic, and anti-fibrotic properties. This broad range of activity provides an opportunity to evaluate ALY688 in multiple disease indications. Data from disease models have been consistent with predicted biologic effects. For example, in ocular models of dry eye and corneal injury, ALY688 decreased inflammation on the ocular surface (both T cell and pro-inflammatory cytokines) and promoted rapid healing (re-epithelization) following corneal injury. Additionally, in models of liver fibrosis, ALY688 reduced inflammation, hepatocyte injury, and fibrosis.
Company Contact:
[email protected]
www.allysta.com
Allysta Media Contact:
Cris Larson, CFO
Allysta Pharmaceuticals
[email protected]
SOURCE: Allysta Pharmaceuticals, Inc.
Get a daily dose of Baltimore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baltimore Star.
More InformationNEW YORK, New York - U.S. stocks were mostly higher Thursday, although the Nasdaq Composite finished modestly behind. This is a market...
SAN JUAN, Puerto Rico: As the global trade war deepens, Puerto Rico is seizing the moment to lure international companies to relocate...
INDIANAPOLIS, Indiana: Eli Lilly's obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk's Wegovy in the...
SHENZHEN, China: China's passenger car sales climbed for the third consecutive month in April, increasing 14.8 percent from a year...
NEW YORK, New York - U.S. stocks were bought up on the Nasdaq Composite and Standard and Poor's 500 while the Dow Jones industrial...
WASHINGTON, D.C.: U.S. worker productivity fell in the first quarter of the year for the first time in nearly three years, leading...
NEW YORK, New York - U.S. stocks were mostly higher Thursday, although the Nasdaq Composite finished modestly behind. This is a market...
SAN JUAN, Puerto Rico: As the global trade war deepens, Puerto Rico is seizing the moment to lure international companies to relocate...
INDIANAPOLIS, Indiana: Eli Lilly's obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk's Wegovy in the...
SHENZHEN, China: China's passenger car sales climbed for the third consecutive month in April, increasing 14.8 percent from a year...
NEW YORK, New York - U.S. stocks were bought up on the Nasdaq Composite and Standard and Poor's 500 while the Dow Jones industrial...
WASHINGTON, D.C.: U.S. worker productivity fell in the first quarter of the year for the first time in nearly three years, leading...